Chronic Pain Market Synopsis:
Chronic Pain Market Size Was Valued at USD 88.2 Billion in 2023, and is Projected to Reach USD 173.4 Billion by 2032, Growing at a CAGR of 7.0% From 2024-2032.
The Chronic pain market refers to the products, services and services that address the disease and help to manage acute and chronic pain that may last several months or years. The causes of chronic pain can include arthritis, nerve problems or disease, or other persistent illnesses. That is why it has economic effects on them, not mentioning the physical and psychological consequences, which will never allow a person to live a comfortable life. Therefore, there is constant demand for pain relief products, such as drugs, gear, and other medical technologies and therapies for patients in different parts of the world. This market is especially important for enhancing patient mobility and decreasing their pain.
Chronic pain market is growing exceedingly across the globe, majorly because of high incidences of chronic diseases and an ageing population globally. Chronic pain situations like osteoarthritis, rheumatoid arthritis, neuropathy, and fibromyalgia have inspired one to look for better treatment solution. Technological changes such as innovation in pain management medication, therapy and enhancing devices that is pervasively transforming the medical industry contributes to the future emergence of this market. Moreover, increased patient and healthcare providers’ knowledge of early diagnosis and appropriate management of chronic pain supplements market growth as well.
Another important driver contributing to the chronic pain market is the increasing awareness of non-opioid pain relief solutions. Due to opioid crisis, attention shifted toward safer approaches such as NSAIDs, nerve blocks, electrical stimulators, and even certain types of psychological therapies as CBT. Managers of healthcare are also working on a multidisciplinary strategy that embraces the use of medicines supplemented by physical therapy, diet changes among other forms of treatment together with psychiatric disorder treatment in an effort to give a comprehensive solution to chronic pain. This change in the approach to treating chronic pain conditions together with rising government focus on funding for pain management will foster sustained growth in the market in the forecast period.

Chronic Pain Market Trend Analysis:
Rise of personalized pain management
- It is very crucial to Note that the current trend that has erupted in the chronic pain market is the concept of personalized pain management. The advancements in genetic science, pharmacogenomics, updated chronic pain diagnosis, and classification systems are allowing prescribers to make decisions about the pharmacological treatment of pain based on the patient personal characteristics and response to medication, type and diagnosis of pain. The rationale for adopting this approach lies in the belief that by identifying individuals with particularly acute sensitivity to pain, it will be possible to deliver enhanced treatments and a major reduction in the levels of failed trials inherent in the management of such pain. personalised treatment strategies may entail change in doses or type of medicines, introduction of technologies like pain control gadgets. It is expected that this will give a new dimension to the market concerning enhancing patient satisfaction, treatment outcomes and reducing side effects.
Expanding Role of Telemedicine
- Telemedicine constitutes a growth opportunity for the chronic pain management sector because of its continued adoption. The virtual nature of telemedicine also means that patients can obtain pain management services they may not be able to receive otherwise, simply because they live in an area with scarce medical services. This is especially so for those who have limited mobility or those in severe pain most of the time. The COVID-19 pandemic has brought the use of telemedicine into a new level, facilitating real time consultations, remote monitoring and even online prescription for chronic pain patient. The emergence of virtual care is expected to remain a key trend supported by its relative availability and ease of access; this opens up a new form of Patient Portability for healthcare providers to connect with their patients to enhance their care experience.
Chronic Pain Market Segment Analysis:
Chronic Pain Market is Segmented on the basis of Type, Application, End User, and Region
By Type, Drugs segment is expected to dominate the market during the forecast period
- Taking a 53.2% market share, drugs are the leading method in the management of chronic pain. Their core interest is on the pharmacological approach for handling chronic pain. Drug therapies include analgesics and anti-inflammatory drugs In this connection, the importance of drug therapies for chronic pain problems is illustrated by them. At the same time, this market presents other devices such as analgesic infusion pumps which are used to deliver drugs to designated parts of the human body with the objective of eradicating chronic pain, a crucial role. With the increasing market, new opportunities for pharmaceuticals and such unique tools as analgesic infusion pumps illustrate how the innovative approach may meet all the chronic pain requirements of a human.
By Indication, Neuropathic segment expected to held the largest share
- Neuropathic pain occupies a unique and significant place in the large category of chronic pain treatment with a remarkable 31.6% market share; and Again, the frequency of neuropathic pain concerning chronic pain diseases cannot be overstated. Market players provide products and services for various illnesses and conditions like Acute Appendicitis, Fibromyalgia, Post-Operative Pain, Bone Fracture, Muscle Sprain/Strain, Cancer Pain, and Arthritic Pain. Each subsegment represents the specificity of chronic pain management that requires segmented strategies for changing the need.
- Neuropathic pain being the central area for the Chronic Pain Treatment Market shows the industry’s commitment to providing the best solutions for diseases caused by nervous system disorders. Chronic Pain Treatment Market offers an elaborate and individualistic approach to a number of sensations of pain that have grouped into several categories within Chronic Pain Treatment Market.
Chronic Pain Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America held the largest share in the chronic pain market in 2023 due to a rising incidence of chronic diseases, a sophisticated healthcare system, and increasing need for pain management solutions. Most specifically, the United States dominates due to the constant development of its healthcare system, a rising number of patients who understand that chronic pain is very treatable, as well as large firms that are already developing and testing pain management drugs and therapies. Based on the available research data in the global chronic pain market, North America is one major consumer that contributed to the market share of 40% in 2023. The focus of research and development in the region along with the availability of modern technologies for the management of pain enhances this region’s operations in this sector. Moreover, a positive reimbursement policy for pain management treatments in the region such as the US has further boosted the growth.
Active Key Players in the Chronic Pain Market:
- Abbott Laboratories (United States)
- AbbVie Inc. (United States)
- AstraZeneca (United Kingdom)
- Bayer AG (Germany)
- Boehringer Ingelheim (Germany)
- Boston Scientific Corporation (United States)
- Eli Lilly and Company (United States)
- GlaxoSmithKline plc (United Kingdom)
- Johnson & Johnson (United States)
- Medtronic plc (Ireland)
- Merck & Co., Inc. (United States)
- Novartis AG (Switzerland)
- Pfizer Inc. (United States)
- Sanofi S.A. (France)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Other Active Players
Key Industry Developments in the Chronic Pain Market:
- In December 2023, the pharmaceutical business Forever Cheer, which currently owns more than ten international patents, selected Hong Kong as the point of entry for international marketing of new pain relief drugs. As its medications to Hong Kong indicates the ever growing global reach of the company aims to have a significant impact on the health care system.
- In August 2023, MOBE and Override two digital health companies partnered to offer a Chronic Pain Shared Savings Model.or the global introduction of its novel pain relief medications. With the launch of its medications from Hong Kong, the company hopes to broaden its global presence and have a big influence on the healthcare sector.
- In August 2023, Two innovators in digital health, MOBE and Override, teamed up to introduce a shared savings scheme for the treatment of chronic pain. Thus, by practice of the behavioural health coaching, and with the use of data analytics, the initiative aims at reducing the other over expenses in health care facilities while affording personalised care to patients with chronic pain.
Chronic Pain Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 88.2 Billion |
Forecast Period 2024-32 CAGR: |
7% |
Market Size in 2032: |
USD 173.4 Billion |
Segments Covered: |
By Type |
|
|
By Indication |
|
||
By End User |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Chronic Pain Market by Type (2018-2032)
4.1 Chronic Pain Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Drugs
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Devices
4.5 Analgesic
4.6 Infusion Pumps
Chapter 5: Chronic Pain Market by Indication (2018-2032)
5.1 Chronic Pain Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Cancer Pain
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Arthritic Pain
5.5 Acute Appendicitis
5.6 Neuropathic Pain
5.7 Post-Operative Pain
5.8 Fibromyalgia
5.9 Migraine
5.10 Bone Fracture
5.11 Muscle Sprain/Strain
Chapter 6: Chronic Pain Market by End User (2018-2032)
6.1 Chronic Pain Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Clinics
6.5 Nursing Homes
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Chronic Pain Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBOTT LABORATORIES (UNITED STATES)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ABBVIE INC. (UNITED STATES)
7.4 ASTRAZENECA (UNITED KINGDOM)
7.5 BAYER AG (GERMANY)
7.6 BOEHRINGER INGELHEIM (GERMANY)
7.7 BOSTON SCIENTIFIC CORPORATION (UNITED STATES)
7.8 ELI LILLY AND COMPANY (UNITED STATES)
7.9 GLAXOSMITHKLINE PLC (UNITED KINGDOM)
7.10 JOHNSON & JOHNSON (UNITED STATES)
7.11 MEDTRONIC PLC (IRELAND)
7.12 MERCK & CO. INC. (UNITED STATES)
7.13 NOVARTIS AG (SWITZERLAND)
7.14 PFIZER INC. (UNITED STATES)
7.15 SANOFI S.A. (FRANCE)
7.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Chronic Pain Market By Region
8.1 Overview
8.2. North America Chronic Pain Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size by Type
8.2.4.1 Drugs
8.2.4.2 Devices
8.2.4.3 Analgesic
8.2.4.4 Infusion Pumps
8.2.5 Historic and Forecasted Market Size by Indication
8.2.5.1 Cancer Pain
8.2.5.2 Arthritic Pain
8.2.5.3 Acute Appendicitis
8.2.5.4 Neuropathic Pain
8.2.5.5 Post-Operative Pain
8.2.5.6 Fibromyalgia
8.2.5.7 Migraine
8.2.5.8 Bone Fracture
8.2.5.9 Muscle Sprain/Strain
8.2.6 Historic and Forecasted Market Size by End User
8.2.6.1 Hospitals
8.2.6.2 Clinics
8.2.6.3 Nursing Homes
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Chronic Pain Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size by Type
8.3.4.1 Drugs
8.3.4.2 Devices
8.3.4.3 Analgesic
8.3.4.4 Infusion Pumps
8.3.5 Historic and Forecasted Market Size by Indication
8.3.5.1 Cancer Pain
8.3.5.2 Arthritic Pain
8.3.5.3 Acute Appendicitis
8.3.5.4 Neuropathic Pain
8.3.5.5 Post-Operative Pain
8.3.5.6 Fibromyalgia
8.3.5.7 Migraine
8.3.5.8 Bone Fracture
8.3.5.9 Muscle Sprain/Strain
8.3.6 Historic and Forecasted Market Size by End User
8.3.6.1 Hospitals
8.3.6.2 Clinics
8.3.6.3 Nursing Homes
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Chronic Pain Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size by Type
8.4.4.1 Drugs
8.4.4.2 Devices
8.4.4.3 Analgesic
8.4.4.4 Infusion Pumps
8.4.5 Historic and Forecasted Market Size by Indication
8.4.5.1 Cancer Pain
8.4.5.2 Arthritic Pain
8.4.5.3 Acute Appendicitis
8.4.5.4 Neuropathic Pain
8.4.5.5 Post-Operative Pain
8.4.5.6 Fibromyalgia
8.4.5.7 Migraine
8.4.5.8 Bone Fracture
8.4.5.9 Muscle Sprain/Strain
8.4.6 Historic and Forecasted Market Size by End User
8.4.6.1 Hospitals
8.4.6.2 Clinics
8.4.6.3 Nursing Homes
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Chronic Pain Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size by Type
8.5.4.1 Drugs
8.5.4.2 Devices
8.5.4.3 Analgesic
8.5.4.4 Infusion Pumps
8.5.5 Historic and Forecasted Market Size by Indication
8.5.5.1 Cancer Pain
8.5.5.2 Arthritic Pain
8.5.5.3 Acute Appendicitis
8.5.5.4 Neuropathic Pain
8.5.5.5 Post-Operative Pain
8.5.5.6 Fibromyalgia
8.5.5.7 Migraine
8.5.5.8 Bone Fracture
8.5.5.9 Muscle Sprain/Strain
8.5.6 Historic and Forecasted Market Size by End User
8.5.6.1 Hospitals
8.5.6.2 Clinics
8.5.6.3 Nursing Homes
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Chronic Pain Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size by Type
8.6.4.1 Drugs
8.6.4.2 Devices
8.6.4.3 Analgesic
8.6.4.4 Infusion Pumps
8.6.5 Historic and Forecasted Market Size by Indication
8.6.5.1 Cancer Pain
8.6.5.2 Arthritic Pain
8.6.5.3 Acute Appendicitis
8.6.5.4 Neuropathic Pain
8.6.5.5 Post-Operative Pain
8.6.5.6 Fibromyalgia
8.6.5.7 Migraine
8.6.5.8 Bone Fracture
8.6.5.9 Muscle Sprain/Strain
8.6.6 Historic and Forecasted Market Size by End User
8.6.6.1 Hospitals
8.6.6.2 Clinics
8.6.6.3 Nursing Homes
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Chronic Pain Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size by Type
8.7.4.1 Drugs
8.7.4.2 Devices
8.7.4.3 Analgesic
8.7.4.4 Infusion Pumps
8.7.5 Historic and Forecasted Market Size by Indication
8.7.5.1 Cancer Pain
8.7.5.2 Arthritic Pain
8.7.5.3 Acute Appendicitis
8.7.5.4 Neuropathic Pain
8.7.5.5 Post-Operative Pain
8.7.5.6 Fibromyalgia
8.7.5.7 Migraine
8.7.5.8 Bone Fracture
8.7.5.9 Muscle Sprain/Strain
8.7.6 Historic and Forecasted Market Size by End User
8.7.6.1 Hospitals
8.7.6.2 Clinics
8.7.6.3 Nursing Homes
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
Chronic Pain Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 88.2 Billion |
Forecast Period 2024-32 CAGR: |
7% |
Market Size in 2032: |
USD 173.4 Billion |
Segments Covered: |
By Type |
|
|
By Indication |
|
||
By End User |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Frequently Asked Questions :
The forecast period in the Chronic Pain Market research report is 2024-2032.
Abbott Laboratories (United States), AbbVie Inc. (United States), AstraZeneca (United Kingdom), Bayer AG (Germany), Boehringer Ingelheim (Germany), Boston Scientific Corporation (United States), Eli Lilly and Company (United States), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Medtronic plc (Ireland), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd. (Israel), and Other Active Players.
The Chronic Pain Market is categorized based on type of Pain, application type, end users of the chronic pain solutions and the four major geographical regions of the world. This market is divided by Type into Drugs, Devices, Analgesic, and Infusion Pumps. By Indication it is divided into Cancer Pain, Arthritic Pain, Acute Appendicitis, Neuropathic Pain, Post-Operative Pain, Fibromyalgia, Migraine, Bone Fracture, Muscle Sprain/Strain. By End User, the market is segmented into Hospitals, Clinics, Nursing Homes. On the basis of geographical, it is divided into North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
The chronic pain space is centered on therapies, treatments, and a broad range of services meant to possibly heal or ease the pain that lasts for more than several months or years. That means acute pain may go away within a day or weeks and comes from inflammation, nerve damage, or other disorders. Concerning the effects, it has physical and mental effects on individuals making them be need poor quality lifed. Thus, the need for pain management including medicines, interventional devices and conservative therapies stays high all over the world. It should be mentioned that this market is critically important for enhancing functionality of patients or decreasing their level of discomfort.
The Chronic Pain Treatment Market size is projected to reach around USD 173.4 Billion in 2032 from USD 88.2 Billion in 2023 with the CAGR of 7.0% during the forecast period of 2024-2033.